Skip to main content

Table 3 Meta-analyzed adjusted risk of incident cardiovascular disease in SHFS and SHS

From: Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study

 

Model 1

Model 2

Model 3

RR

95% CI

p-value

RR

95% CI

p-value

RR

95% CI

p-value

Cer-16

1.71

(1.18, 2.48)

0.005

1.54

(1.07, 2.23)

0.021

1.85

(1.05, 3.25)

0.033

Cer-20

1.27

(0.98, 1.65)

0.072

1.30

(1.01, 1.68)

0.044

1.03

(0.69, 1.54)

0.876

Cer-22

1.09

(0.76, 1.57)

0.640

1.06

(0.75, 1.5)

0.741

0.70

(0.42, 1.16)

0.162

Cer-24

1.13

(0.77, 1.64)

0.534

1.06

(0.74, 1.52)

0.738

0.65

(0.38, 1.12)

0.122

SM-16

1.62

(0.84, 3.14)

0.154

1.26

(0.65, 2.46)

0.492

2.04

(0.82, 5.05)

0.125

SM-20

0.80

(0.52, 1.24)

0.328

0.75

(0.48, 1.18)

0.209

0.50

(0.27, 0.93)

0.028

SM-22

0.85

(0.57, 1.27)

0.414

0.75

(0.51, 1.13)

0.169

0.48

(0.26, 0.87)

0.016

SM-24

0.88

(0.61, 1.25)

0.470

0.78

(0.54, 1.14)

0.198

0.52

(0.3, 0.89)

0.018

  1. Model 1 includes terms for age, sex, and study site (SHFS only). Model 2 additionally includes terms for education, smoking, physical activity, BMI, waist circumference, LDL-cholesterol, systolic blood pressure, treated hypertension, duration of diabetes, type of diabetes medication used, and treated hyperlipidemia. Model 3 further adjusts for one of the other species: Cer-16 and SM-16 models include adjustment for Cer-22 and SM-22, respectively; Cer-20, -22, -24, and SM-20, -22, and -24 models include adjustment for Cer-16 and SM-16, respectively
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840